Most patients with mutated WT1 (n=35, 73%) harbored at least one co-occurring mutation in the AML blasts, with the most common being FLT3-ITD (n=19, 40%) followed by NRAS mutations (n=11, 23%, Table 1 and Figure 1(b)). This evidence concerns the gene WT1 and acute myeloid leukemia.